NASDAQ · Biotechnology

BioLineRx Ltd. (BLRX) Stock

$2.85 -2.45% NASDAQ: BLRX Healthcare

BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer.

Valuation

MetricValue
Price$2.85
Market Cap$12.39M
P/E Ratio-1.36
P/B Ratio0.78
P/S Ratio9.11
EPS (TTM)$-0.29
52-Week High$4.75
52-Week Low$2.15
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-47.86%
ROA-22.97%
ROCE-43.58%
Gross Margin74.67%
Operating Margin-780.21%
Net Margin-633.83%
Debt/Equity0.54
Current Ratio1.58

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$5.0M$29.0M$1.0M
Operating Profit$-25.0M$-29.0M$-50.0M$-20.0M$-10.0M
Net Profit$-27.0M$-25.0M$-61.0M$-9.0M$-1.0M
EPS$-0.61$-0.48$-0.94$-0.12$-0.29
Op Margin——-1035.3%-70.5%-871.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$81.0M$76.0M$64.0M$39.0M$41.0M
Total Liabilities$13.0M$26.0M$51.0M$25.0M$18.0M
Cash$13.0M$11.0M$4.0M$10.0M$3.0M
Borrowings$5.0M$12.0M$12.0M$15.0M$10.0M

Latest News

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 PR Newswire · Jul 20, 2026 BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model PR Newswire · Jul 8, 2026 BioLine Rx Ltd (BLRX) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ... GuruFocus.com · Jun 3, 2026 BLRX: First Quarter 2026 Results Zacks Small Cap Research · May 28, 2026 BioLineRx Shares Advance After First Patient Enrolled in GLIX1 Cancer Study (BLRX) InvestorsHub · May 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-24.0M$-26.0M$-23.0M$-44.0M$-8.0M
Investing Cash Flow$-38.0M$4.0M$1.0M$29.0M$-9.0M
Financing Cash Flow$11.0M$0$3.0M$0$-1.0M
Net Cash Flow$-4.0M$-2.0M$-6.0M$6.0M$-7.0M
Free Cash Flow$-24.0M$-27.0M$-23.0M$-44.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-1.72
FCF Yield-62.13%
Quick Ratio1.43
Interest Coverage-9.83
Return 1Y-36.56%
Return 3Y-95.63%
Return 5Y-97.83%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About BioLineRx Ltd.

BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.

BioLineRx Ltd. is headquartered in IL.

BioLineRx Ltd. (BLRX) stock trades at $2.85 with a market capitalization of $12.39M. The stock is valued at a price-to-earnings (P/E) ratio of -1.36, price-to-book of 0.78, price-to-sales of 9.11. Over the past 52 weeks the stock has ranged between $2.15 and $4.75, and currently trades 40.0% below its 52-week high.

On profitability, BioLineRx Ltd. generates a return on equity (ROE) of -47.86%, return on capital employed of -43.58%, an operating margin of -780.21%, a net profit margin of -633.83%.

Official website: www.biolinerx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides